Accelrys employees can let out a collective "phew." Their company has extended its "long-standing" customer relationship with Pfizer, meaning the San Diego-based scientific software provider will keep getting business from one of the largest drugmakers in the world.
Pfizer ($PFE) is testing the online-sales waters with a new program to sell Viagra directly to consumers. It's a natural choice: Makers of erectile dysfunction drugs have been working on packaging and formulation changes to make it easier--and more discreet--for men to use them.
The popular Z-Pak antibiotic, linked to heart-rhythm problems in March, may not be risky for the average patient, a new study suggests.
Pfizer catapulted itself into the vaccine big leagues in 2009 by merging with Wyeth, and continued demand for Prevnar 13 has seen it consolidate its position. Analysts predict its sales could dwarf other vaccines--hitting $6.7 billion in 2018--but recent quarters suggest it will be a bumpy ride.
Like many of its rivals, Pfizer reported a dip in quarterly sales: 9%, to be exact, to $13.5 billion. But worse for Pfizer, the decline was bigger than analysts had expected.
Jockeying for a leading position in the high-stakes race to develop a new generation of blockbuster diabetes drugs, Merck is hitching a ride with Pfizer's late-stage SGLT2 candidate, ertugliflozin (PF-04971729).
European authorities have battered expectations for Pfizer's rheumatoid arthritis pill Xeljanz, spurning the drug giant's request for approval over concerns about the risk-benefit profile. The surprise rejection cools the company's run of regulatory success, which included 5 FDA approvals in 2012.
Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.
BIO and the International Federation of Pharmaceutical Manufacturers & Associations warn that more funding is needed to maintain current immunization rates while adding new vaccines to programs.
While the success rate in developing new disease treatments remains alarmingly low, a cadre of R&D executives from some of the world's biggest drug developers insisted at BIO that they've zeroed in on a number of ways to boost the chance a promising drug will actually reach patients.